Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cancer vaccine - ImmunoRestoration

Next Previous
Search
Drug Profile

Cancer vaccine - ImmunoRestoration

Alternative Names: DC-1

Latest Information Update: 30 Jun 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ImmunoRestoration
  • Developer H. Lee Moffitt Cancer Center and Research Institute; ImmunoRestoration
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II HER2 positive breast cancer
  • No development reported Cancer

Most Recent Events

  • 28 Jun 2023 No recent reports of development identified for clinical-Phase-Unknown development in Cancer in USA (Parenteral)
  • 02 Jun 2023 Efficacy and adverse events data from a phase I/II trial in HER2-positive breast cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
  • 28 Oct 2021 Phase-I/II clinical trials in HER2-positive-breast-cancer (Neoadjuvant therapy) in USA (Intratumoural) (NCT05325632)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top